Safety Evaluation of Combined Ipratropium Bromide and Levosalbutamol Therapy in Patients with Lung Diseases: A Prospective and Cross-Sectional Observational Study

Background

Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Tuberculosis Obstructive Pulmonary Disease (TOPD) are chronic inflammatory respiratory disorders associated with bronchial hyperactivity. This study aims to assess the safety profile of Nebulizer Duolin (Ipratropium bromide + Levosalbutamol) in patients with these conditions.

Objectives

The primary objective is to investigate the safety profile of Nebulized Duolin in patients with COPD, Asthma, and TOPD.

Materials and Methods

A prospective observational study was conducted at Dhiraj Hospital, enrolling 73 subjects diagnosed with Asthma, COPD, and TOPD. Patients from the Inpatient Department (IPD) and Intensive Care Unit (ICU) were provided with a Patient Information Sheet, and consent was obtained. Safety assessments were conducted through patient interviews after Nebulizer Duolin administration.

Results

Following Duolin nebulization, 20.5% of the population experienced side effects, while 79.5% showed no adverse reactions. The majority (78.08%) of the enrolled subjects were male, with a mean age of 55.72±14. COPD was the most prevalent condition (60%), followed by Asthma and TOPD. Common symptoms included breathlessness (93.15%) and cough (83.56%).

Conclusion

Nebulizer Duolin, combining Ipratropium bromide and Levosalbutamol, demonstrates a favourable safety profile as a treatment option for obstructive airway diseases (COPD, Asthma, and TOPD). This study provides insights for education and quality improvement to minimize medication-related side effects and enhance overall benefits.